Non-Hodgkin's Lymphoma Archives - DelveInsight

Non-Hodgkin's Lymphoma

recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain
Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Th...

Cidara Therapeutics Inks USD 780M Deal with J&J The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&J came. Cidara Therapeutics ha...


CAR T cell therapy
66 Year Ohio Woman Becomes Cancer Free, Thanks to CAR T Cell Therapy

In a groundbreaking clinical trial, a 66-year-old Ohio woman became the first patient to become cancer free through the CAR T Cell Therapy. In August this year, Denise Kennan had participated in th...


Non-Hodgkin Lymphoma: “Malignant Growth of White Blood Cells”

Non-Hodgkin Lymphoma (NHL) is the leading cause of mortality and morbidity worldwide. It begins in lymphocytes present in lymph nodes of body parts such as neck or chest or under the arms. It widel...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.